Replies to post #242255 on Innovation Pharmaceuticals Inc (IPIX)

[wsbc]

...just last night?

This has been an ongoing curiosity for some time now with Otezla being possibly bettered by Prurisol... hence our need for those P2b results, stat.

Guessing the oncology team at CELG can likely take over for any sort of K research/re-formulation etc. I Think the point that it's functional was proven already. Now the applications and further trials are required, and cash is needed. Perhaps Menon is not, in the scheme of things, if CELG acquisition is potentially at-hand.

Last night I started wondering if Celgene was interested in Kevetrin. Today I'm even more curious.

[Amatuer17]

What else you dream of?

Dr Menon salary was cut and it was a signal that K is dead. Today’s announcement clearly says

“Dr. Menon of the termination of his continued employment with the Company in order for the Company to further focus its resources on clinical trials for its lead drug candidates.”

It shows that the he is no more needed and his primary contribution which was K is dead.

Thinking that K had left any life after they shelved it 2 years back is stupidity. Same as talking about MTA with JnJ